์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

์ฃผ์š” ๋ฌธ์„œ

๋ชจ๋“  ๋ฌธ์„œ ๋ณด๊ธฐ

SAB2502131

Anti-TNNT2 (C-terminal) antibody produced in goat

affinity isolated antibody, buffered aqueous solution

๋™์˜์–ด(๋“ค):

CMH2, CMPD2, LVNC6, MGC3889, troponin T type 2 (cardiac)

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ

๋ณด๊ธฐ ๋ณ€๊ฒฝ

์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA (i), WB
Citations:
2
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

biological source

goat

Quality Level

100

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human, pig, cat, canine, rat, mouse

technique(s)

indirect ELISA: suitable, western blot: suitable

UniProt accession no.

P45379

shipped in

wet ice

storage temp.

−20ยฐC

target post-translational modification

unmodified

Gene Information

human ... TNNT2(7139)

Immunogen

Peptide with sequence C-RNRINDNQKVSKT, from the C-terminal region of the protein sequence according to NP_000355.2; NP_001001430.1; NP_001001431.1; NP_001001432.1

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Still not finding the right product?

์ œํ’ˆ ์„ ํƒ ๋„๊ตฌ}๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์„ ํƒ์˜ ํญ์„ ์ขํ˜€๋ณด์„ธ์š”.

์ €์žฅ ๋“ฑ๊ธ‰

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our ๋ฌธ์„œ section.

๋„์›€์ด ํ•„์š”ํ•˜์‹œ๋ฉด ์—ฐ๋ฝํ•˜์„ธ์š”. ๊ณ ๊ฐ ์ง€์› ๋ถ€์„œ

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Agnese Petrera et al.
Journal of translational medicine, 14(1), 153-153 (2016-06-02)
Myocardial infarction (MI) is a major cause of heart failure. The carboxypeptidase cathepsin A is a novel target in the treatment of cardiac failure. We aim to show that recently developed inhibitors of the protease cathepsin A attenuate post-MI heart
Parisha P Shah et al.
Cell stem cell, 28(5), 938-954 (2021-02-03)
Pathogenic mutations in LAMIN A/C (LMNA) cause abnormal nuclear structure and laminopathies. These diseases have myriad tissue-specific phenotypes, including dilated cardiomyopathy (DCM), but how LMNA mutations result in tissue-restricted disease phenotypes remains unclear. We introduced LMNA mutations from individuals with

๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
SAB2502131-100UG04061837688218